Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances
Therapeutic development for metabolic-dysfunction-associated steatohepatitis (MASH) trails behind the success seen in hepatitis C virus (HCV) management. HCV, characterized by a viral etiology, benefits from direct-acting antivirals (DAAs) targeting viral proteins, achieving cure rates exceeding 90%...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Gastroenterology Insights |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2036-7422/15/4/66 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846104505807011840 |
|---|---|
| author | Caesar Ferrari Bilal Ashraf Zainab Saeed Micheal Tadros |
| author_facet | Caesar Ferrari Bilal Ashraf Zainab Saeed Micheal Tadros |
| author_sort | Caesar Ferrari |
| collection | DOAJ |
| description | Therapeutic development for metabolic-dysfunction-associated steatohepatitis (MASH) trails behind the success seen in hepatitis C virus (HCV) management. HCV, characterized by a viral etiology, benefits from direct-acting antivirals (DAAs) targeting viral proteins, achieving cure rates exceeding 90%. In contrast, MASH involves complex metabolic, genetic, and environmental factors, presenting challenges for drug development. Non-invasive diagnostics like ultrasound, FibroScan, and serum biomarkers, while increasingly used, lack the diagnostic accuracy of liver biopsy, the current gold standard. This review evaluates therapies for MASH, including resmetirom (Rezdiffra) and combinations like pioglitazone and vitamin E, which show potential but offer modest improvements due to MASH’s heterogeneity. The limited efficacy of these treatments highlights the need for multi-targeted strategies addressing metabolic and fibrotic components. Drawing parallels to HCV’s success, this review emphasizes advancing diagnostics and therapies for MASH. Developing effective, patient-specific therapies is crucial to closing the gap between MASH and better-managed liver diseases, optimizing care for this growing health challenge. |
| format | Article |
| id | doaj-art-8159b531bd9b4ef4a4345095aec647d9 |
| institution | Kabale University |
| issn | 2036-7414 2036-7422 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Gastroenterology Insights |
| spelling | doaj-art-8159b531bd9b4ef4a4345095aec647d92024-12-27T14:27:42ZengMDPI AGGastroenterology Insights2036-74142036-74222024-10-0115494496210.3390/gastroent15040066Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment AdvancesCaesar Ferrari0Bilal Ashraf1Zainab Saeed2Micheal Tadros3Department of Gastroenterology and Hepatology, Albany Medical College, Albany, NY 12208, USAHCA Houston Healthcare Kingwood, Kingwood, TX 77339, USAHouston Methodist Baytown Hospital, Baytown, TX 77521, USADepartment of Gastroenterology and Hepatology, Albany Medical College, Albany, NY 12208, USATherapeutic development for metabolic-dysfunction-associated steatohepatitis (MASH) trails behind the success seen in hepatitis C virus (HCV) management. HCV, characterized by a viral etiology, benefits from direct-acting antivirals (DAAs) targeting viral proteins, achieving cure rates exceeding 90%. In contrast, MASH involves complex metabolic, genetic, and environmental factors, presenting challenges for drug development. Non-invasive diagnostics like ultrasound, FibroScan, and serum biomarkers, while increasingly used, lack the diagnostic accuracy of liver biopsy, the current gold standard. This review evaluates therapies for MASH, including resmetirom (Rezdiffra) and combinations like pioglitazone and vitamin E, which show potential but offer modest improvements due to MASH’s heterogeneity. The limited efficacy of these treatments highlights the need for multi-targeted strategies addressing metabolic and fibrotic components. Drawing parallels to HCV’s success, this review emphasizes advancing diagnostics and therapies for MASH. Developing effective, patient-specific therapies is crucial to closing the gap between MASH and better-managed liver diseases, optimizing care for this growing health challenge.https://www.mdpi.com/2036-7422/15/4/66metabolic-dysfunction-associated fatty liver disease (MAFLD)metabolic-dysfunction-associated steatohepatitis (MASH)hepatitis Cdirect-acting antivirals (DAAs)liver fibrosisnon-invasive diagnostics |
| spellingShingle | Caesar Ferrari Bilal Ashraf Zainab Saeed Micheal Tadros Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances Gastroenterology Insights metabolic-dysfunction-associated fatty liver disease (MAFLD) metabolic-dysfunction-associated steatohepatitis (MASH) hepatitis C direct-acting antivirals (DAAs) liver fibrosis non-invasive diagnostics |
| title | Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances |
| title_full | Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances |
| title_fullStr | Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances |
| title_full_unstemmed | Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances |
| title_short | Understanding Why Metabolic-Dysfunction-Associated Steatohepatitis Lags Behind Hepatitis C in Therapeutic Development and Treatment Advances |
| title_sort | understanding why metabolic dysfunction associated steatohepatitis lags behind hepatitis c in therapeutic development and treatment advances |
| topic | metabolic-dysfunction-associated fatty liver disease (MAFLD) metabolic-dysfunction-associated steatohepatitis (MASH) hepatitis C direct-acting antivirals (DAAs) liver fibrosis non-invasive diagnostics |
| url | https://www.mdpi.com/2036-7422/15/4/66 |
| work_keys_str_mv | AT caesarferrari understandingwhymetabolicdysfunctionassociatedsteatohepatitislagsbehindhepatitiscintherapeuticdevelopmentandtreatmentadvances AT bilalashraf understandingwhymetabolicdysfunctionassociatedsteatohepatitislagsbehindhepatitiscintherapeuticdevelopmentandtreatmentadvances AT zainabsaeed understandingwhymetabolicdysfunctionassociatedsteatohepatitislagsbehindhepatitiscintherapeuticdevelopmentandtreatmentadvances AT michealtadros understandingwhymetabolicdysfunctionassociatedsteatohepatitislagsbehindhepatitiscintherapeuticdevelopmentandtreatmentadvances |